Compare Stocks

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASLN ASLAN Pharmaceuticals	$0.49	$0.61	$0.39 ▼ $4.69	$8.03M	1.45	876,959 shs	152,904 shs
ATXI Avenue Therapeutics	$0.14	$0.15	$0.11 ▼ $1.28	$5.98M	-0.24	4.65 million shs	810,701 shs
KZIA Kazia Therapeutics	$0.34 +17.1%	$0.29	$0.19 ▼ $1.68	$5.61M	2.12	778,873 shs	322,614 shs
SIOX Sio Gene Therapies	$0.48 +1.7%	$0.46	$0.25 ▼ $0.50	N/A	1.14	N/A	40,400 shs
ZSAN Zosano Pharma	$0.00	$3.90	$0.46 ▼ $37.45	$1K	3.3	425,375 shs	5,685 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASLN ASLAN Pharmaceuticals	-2.69%	-13.74%	-24.35%	-6.33%	-86.45%
ATXI Avenue Therapeutics	+5.28%	-10.42%	-16.44%	-8.10%	-88.56%
KZIA Kazia Therapeutics	-5.21%	-36.74%	+29.97%	-15.41%	-78.44%
SIOX Sio Gene Therapies	0.00%	0.00%	0.00%	+22.75%	+19.17%
ZSAN Zosano Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASLN ASLAN Pharmaceuticals	2.6118 of 5 stars	3.5	5.0	0.0	0.0	2.3	0.8	0.6
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SIOX Sio Gene Therapies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASLN ASLAN Pharmaceuticals	3.00	Buy	$11.33	2,208.21% Upside
ATXI Avenue Therapeutics	3.00	Buy	N/A	N/A
KZIA Kazia Therapeutics	N/A	N/A	N/A	N/A
SIOX Sio Gene Therapies	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ASLN, ZSAN, SIOX, ATXI, and KZIA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2024	ASLN ASLAN Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
3/18/2024	ASLN ASLAN Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $9.00
3/13/2024	ASLN ASLAN Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$15.00 ➝ $10.00

(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASLN ASLAN Pharmaceuticals	$12M	0.67	N/A	N/A	$0.60 per share	0.82
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$0.03 per share	N/A
KZIA Kazia Therapeutics	$20K	280.31	N/A	N/A	$0.50 per share	0.69
SIOX Sio Gene Therapies	N/A	N/A	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	$790K	0.00	N/A	N/A	$9.74 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASLN ASLAN Pharmaceuticals	-$44.22M	-$2.74	N/A	∞	N/A	N/A	-862.59%	-82.83%	4/26/2024 (Estimated)
ATXI Avenue Therapeutics	-$10.38M	-$1.27	N/A	∞	N/A	N/A	N/A	-335.11%	5/10/2024 (Estimated)
KZIA Kazia Therapeutics	-$13.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SIOX Sio Gene Therapies	-$71.89M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	-$29.92M	-$14.50	N/A	∞	N/A	-8,375.11%	-177.06%	-119.14%	N/A

Latest ASLN, ZSAN, SIOX, ATXI, and KZIA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/18/2024	Q4 2023	ATXI Avenue Therapeutics	N/A	$0.56	+$0.56	$0.56	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	N/A	N/A	N/A	N/A	N/A
SIOX Sio Gene Therapies	N/A	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASLN ASLAN Pharmaceuticals	N/A	2.11	2.11
ATXI Avenue Therapeutics	N/A	1.55	1.55
KZIA Kazia Therapeutics	N/A	0.71	N/A
SIOX Sio Gene Therapies	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	1.61	1.61

Ownership

Institutional Ownership

Company	Institutional Ownership
ASLN ASLAN Pharmaceuticals	58.82%
ATXI Avenue Therapeutics	17.34%
KZIA Kazia Therapeutics	30.89%
SIOX Sio Gene Therapies	N/A
ZSAN Zosano Pharma	N/A

Insider Ownership

Company	Insider Ownership
ASLN ASLAN Pharmaceuticals	4.69%
ATXI Avenue Therapeutics	1.80%
KZIA Kazia Therapeutics	1.00%
SIOX Sio Gene Therapies	3.40%
ZSAN Zosano Pharma	2.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ASLN ASLAN Pharmaceuticals	34	16.35 million	15.58 million	Optionable
ATXI Avenue Therapeutics	3	44.26 million	43.46 million	Not Optionable
KZIA Kazia Therapeutics	2,021	16.34 million	16.18 million	Optionable
SIOX Sio Gene Therapies	12	N/A	N/A	No Data
ZSAN Zosano Pharma	40	4.90 million	4.78 million	Not Optionable

ASLN, ZSAN, SIOX, ATXI, and KZIA Headlines

Source	Headline
	HOOK HOOKIPA Pharma Inc. seekingalpha.com - April 12 at 10:11 PM
	Nachrichten - Weitere Nachrichten wallstreet-online.de - January 9 at 2:39 PM
	LISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy plan pbs.org - December 6 at 7:44 AM
	Der Börsen-Tag: Diese US-Aktie stürzte nachbörslich ab n-tv.de - August 22 at 3:36 PM
	East Bay Business News bizjournals.com - May 18 at 9:49 PM
	Mankind Pharma IPO opens on April 25, listing scheduled for May 9 moneycontrol.com - April 27 at 4:20 PM
	Astellas Pharma forbes.com - April 6 at 12:00 PM
	Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation finance.yahoo.com - February 5 at 12:11 PM
	FTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by orders washingtonexaminer.com - January 23 at 3:25 PM
	Zosano Pharma Corporation (ZSANQ) ca.finance.yahoo.com - November 5 at 6:33 PM
	Now bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lilly endpts.com - October 13 at 11:22 AM
	Bankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giants msn.com - October 12 at 2:32 PM
	Bankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of Claims marketwatch.com - August 28 at 7:45 PM
	East Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 million bizjournals.com - August 27 at 4:10 PM
	Zosano Pharma Corp (ZSANQ) investing.com - August 25 at 12:28 AM
	East Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M bizjournals.com - July 26 at 8:27 PM
	A Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M. bizjournals.com - July 26 at 8:27 PM
	Zosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8 dbtnews.com - June 3 at 11:27 AM
	Zosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSAN marketwatch.com - June 2 at 3:26 PM
	Why Zosano Pharma Shares Are Getting Hammered Today msn.com - June 2 at 3:26 PM
	Zosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46% seekingalpha.com - June 2 at 10:26 AM
	Cash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSAN marketwatch.com - June 2 at 10:26 AM
	East Bay migraine patch developer files for bankruptcy bizjournals.com - June 2 at 10:26 AM
	Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11 finance.yahoo.com - June 2 at 10:26 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ASLAN Pharmaceuticals

NASDAQ:ASLN

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Avenue Therapeutics

NASDAQ:ATXI

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.

Kazia Therapeutics

NASDAQ:KZIA

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

Sio Gene Therapies

NASDAQ:SIOX

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

Zosano Pharma

NASDAQ:ZSAN

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial